21AO image
Deposition Date 2025-12-05
Release Date 2026-05-06
Last Version Date 2026-05-06
Entry Detail
PDB ID:
21AO
Keywords:
Title:
Epitope and functional classification of human neutralizing antibodies against SFTSV Gn
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Expression System(s):
Method Details:
Experimental Method:
Resolution:
2.85 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:BD70-4003 Heavy chain
Chain IDs:A
Chain Length:125
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:BD70-4003 light chain
Chain IDs:B
Chain Length:107
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Glycoprotein N
Gene (Uniprot):GP
Chain IDs:C (auth: H)
Chain Length:321
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Human monoclonal antibodies that target the SFTSV glycoprotein Gn head from four neutralizing epitope groups.
Cell Rep 45 117248 117248 (2026)
PMID: 41955097 DOI: 10.1016/j.celrep.2026.117248

Abstact

Severe fever with thrombocytopenia syndrome virus (SFTSV) is a lethal bunyavirus lacking approved countermeasures. From SFTS survivors, we isolate 84 human monoclonal antibodies (mAbs) against the viral glycoproteins Gn and Gc. Gn-specific mAbs demonstrate superior neutralization breadth and potency compared to the restricted neutralizing activity observed with Gc. Using a high-throughput yeast display deep mutational scanning (DMS) platform, we classify Gn-head mAbs into eight epitope groups, among which four groups (IA, ID, IIIA, and IIIB) confer neutralization. Notably, mAbs BD70-4003 (group IA) and BD70-4017 (group IIIA) exhibit broad neutralization and provide 100% protection in a lethal mouse model. Cryo-electron microscopy (cryo-EM) structural analysis of these mAbs in complex with the Gn head reveals their binding interfaces, directly validating the epitope residues identified by DMS. Our study delineates the antigenic landscape of SFTSV Gn, identifies potent therapeutic candidates, and establishes DMS coupled with structural validation as a powerful framework for antibody discovery against bunyaviruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback